• As part of its risk management plan, Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA as the study sponsor is conducting a post-authorization safety study (PASS) using data from ENEIDA, a large, prospectively maintained registry of patients with inflammatory bowel disease in Spain in the setting of routine clinical practice. Founded in 2006, ENEIDA has not previously been used in a PASS.
OBJECTIVE Overall Study Objectives
• At planned completion in 2023 (using data from September 2013 until May 2022), the study intends to provide comparative data on the risk of colectomy due to intractable disease and of advanced colonic neoplasia (ACN) in patients with UC treated with golimumab, other anti-TNFα agents, or thiopurines. The incidence of hepatosplenic T-cell lymphoma (HSTCL) will be described. Figure 1 shows the overall PASS objectives, including the scope of the annual progress reports and the final analysis. 
Objectives for This Presentation

DISCUSSION
• The Spanish ENEIDA registry has allowed for the following:
-Accrual of patients in the 3 study cohorts -Identification of study outcomes -Acquisition of the information required for the conduct of this EMA-requested PASS
• Until May 2017, the number of patients exposed to golimumab and the number of outcomes have been limited. Patients will be enrolled in the study through May 2022.
• Patients with UC enrolled in the 2 anti-TNFα agent cohorts (i.e., golimumab and other anti-TNFα agents) appear to have similar characteristics. Those enrolled in the thiopurines cohort appear to have less severe UC, which is expected because treatment guidelines recommend the use of an anti-TNFα agent when thiopurines are not sufficient to control the disease.
• The 3 study cohorts were not mutually exclusive, and patients could be in more than 1 cohort if inclusion and exclusion criteria were met. Thus, robust comparability of cohorts is currently limited. Time-dependent analytic methods will be employed in the final analysis to address this limitation.
• Importantly, outcomes may have been counted several times in patients enrolled in > 1 inception cohort (i.e., exposed to > 1 study drug) and thus may not necessarily represent individual outcomes.
CONCLUSIONS
• Based on the preliminary results presented: -The ENEIDA registry is a useful data source to study patients with UC in Spain.
-Extended study periods are needed for less common outcomes.
RESULTS
• Figure 
METHODS
Data Source
• The main source of data for the study is the Spanish inflammatory bowel disease registry, ENEIDA, owned by the Spanish task force on Crohn's disease and UC (GETECCU). (See Figure  2 and Box 1 for main characteristics and organization of the registry.)
• The final analyses will also use data obtained from the medical charts of patients identified in the ENEIDA registry (see step 6 of Figure 2 ).
PASS Study Population
• Adults with UC newly prescribed golimumab, other anti-TNFα agents, or thiopurines from September 2013 through May 2017 (through May 2022 for the final analyses) were included.
• Figure 3 presents the assembly of the 3 study cohorts and the specific inclusion and exclusion criteria.
• Patients may have qualified for up to 3 study cohorts based on first use of each study drug during the study period. Patients could have switched therapies and, if so, were included in all qualifying cohorts.
Analysis
• Descriptive statistics of patient characteristics at study cohort entry 
